Hybridoma Sequencing Service: Secure Your Monoclonal Antibody's Future

Online Inquiry

At Creative Biolabs, we understand that a monoclonal antibody produced by a hybridoma cell line is an invaluable asset. Our industry-leading Hybridoma Sequencing Services provide the ultimate insurance policy for your antibody. By determining the precise nucleotide sequence of the variable heavy (VH) and variable light (VL) chains, we immortalize your unique monoclonal antibody. This critical data empowers you to move beyond the limitations of hybridoma culture into the flexible, reproducible, and scalable world of recombinant antibody production, ensuring the security, consistency, and future of your project.

Discuss Your Project Today

Antibody affinity. (Creative Biolabs Authorized).

The Challenge: The Inherent Risks of Hybridoma Cell Lines

Hybridoma technology was a revolution, but it is not without its drawbacks. Relying solely on a cell line for your antibody supply chain introduces significant risks that can jeopardize your entire project pipeline.

Genetic Drift and Somatic Hypermutation: Hybridoma cells are living entities that can undergo genetic changes with each passage. This can lead to decreased antibody expression, altered binding affinity, or even complete loss of function over time.
Cell Line Loss or Contamination: Physical loss of a cryopreserved vial, contamination with mycoplasma or other cell lines, or a simple freezer failure can result in the irreversible loss of your antibody.
Batch-to-Batch Variability: Subtle changes in cell culture conditions, media, or the health of the hybridoma cells can lead to significant variations between different production lots, impacting experimental reproducibility and quality control.
Intellectual Property and Patent Filing: To secure robust intellectual property rights for a therapeutic or diagnostic antibody, providing the exact amino acid and nucleotide sequence is a fundamental requirement.
Limitations in Antibody Engineering: A hybridoma-produced antibody is fixed in its format (isotype, species). Without the sequence, you cannot perform critical modifications like humanization, isotype switching, or engineering into advanced formats like bispecific antibodies or scFv fragments.

Our Solution: State-of-the-Art Hybridoma Sequencing Platform

Creative Biolabs has developed a proprietary, multi-platform approach to hybridoma sequencing that guarantees unparalleled accuracy, speed, and comprehensiveness. We combine the latest in Next-Generation Sequencing (NGS) technology with sophisticated bioinformatics to deliver a complete and verified sequence of your antibody's genetic blueprint.

Our platform is meticulously designed to overcome the common challenges of hybridoma sequencing, such as identifying low-expressing chains, dealing with multiple V-genes from the myeloma fusion partner, and ensuring full coverage of the variable domains.

Key Features of Our Hybridoma Sequencing Services:

Guaranteed 100% Accuracy: We utilize a multi-clone sequencing strategy and cross-validation to ensure every nucleotide is correctly identified.
Advanced Next-Generation Sequencing (NGS) Technology: Our NGS-based workflow provides deep coverage, allowing for the identification of multiple antibody variants and ensuring the correct, functional sequence is reported.
5' RACE Methodology: We employ an advanced Rapid Amplification of cDNA Ends (RACE) method that is independent of conserved primer sets, enabling us to sequence any antibody from any species and isotype without bias.
Multi-Species & Multi-Isotype Capability: We have extensive experience sequencing monoclonal antibodies from various species, including mouse, rat, hamster, rabbit, and more, across all isotypes (e.g., IgG, IgM, IgA, IgE).
Comprehensive Data and Reporting: Our deliverables go beyond just the sequence. A detailed project report, as well as vectors containing the antibody constructs, are delivered to the client at the end of the project.
Rapid Turnaround Time: Receive your complete, verified antibody sequence within 3 weeks.

Our Advanced Hybridoma Sequencing Workflow

Our process is optimized for quality and speed, ensuring a seamless experience from sample submission to data delivery.

Sample Receipt & QC: Receive your hybridoma cells or purified mAb. We perform stringent quality control to ensure sample viability.
mRNA Extraction: Total RNA or mRNA is isolated from the hybridoma cells using optimized protocols that preserve RNA integrity.
Reverse Transcription & 5' RACE: The mRNA is reverse-transcribed into more stable cDNA. We then use our proprietary 5' RACE-PCR to specifically amplify the full variable regions of both the heavy and light chains.
NGS Library Preparation & Sequencing: The amplified VH and VL products are prepared into libraries for high-throughput Next-Generation Sequencing, generating millions of reads for deep coverage.
Bioinformatics Analysis & Assembly: Our powerful bioinformatics pipeline processes the raw data. Reads are assembled, and the myeloma partner background is filtered out. We identify all productive heavy and light chain sequences and build a consensus.
Sequence Verification & Annotation: The final consensus sequence is rigorously verified. We annotate key regions, including the leader peptide, framework regions (FR), and all three complementarity-determining regions (CDRs).
Final Report & Delivery: You receive a comprehensive report supporting data, ready for patent applications or recombinant expression.

Service Specifications Table

Feature	Specification
Input Material	Hybridoma cells (>1x10⁶ cells, frozen pellet or live culture), or Purified Monoclonal Antibody (>100 µg)
Species	Mouse, Rat, Hamster, Rabbit, and other species (inquire for details)
Isotypes	All isotypes and subtypes (IgG, IgM, IgA, IgE, etc.)
Technology	Proprietary 5' RACE, Next-Generation Sequencing (NGS), Sanger Sequencing (for verification)
Turnaround Time	1-2 weeks standard
Deliverables	A detailed project report, as well as vectors containing the antibody constructs.
Accuracy	100% accuracy guaranteed

Applications: Unlock the Full Potential of Your Antibody

With the precise sequence in hand, the possibilities are limitless.

Recombinant Antibody Production: The most crucial application. Convert your antibody to a recombinant format for stable, large-scale, and highly consistent GMP-grade manufacturing.
Antibody Humanization & Engineering: Reduce the immunogenicity of murine antibodies for therapeutic applications through our expert humanization services.
Affinity Maturation: Modify the CDRs to enhance the binding affinity and specificity of your antibody for improved performance.
Isotype Switching: Easily change the antibody's effector function by cloning the variable regions into different constant region backbones (e.g., mouse IgG1 to human IgG4).
Develop Advanced Formats: Use the VH and VL sequences as building blocks for creating bispecific antibodies, antibody-drug conjugates (ADCs), scFv, Fab fragments, and CAR-T constructs.
Intellectual Property Protection: Secure your invention with a definitive sequence for patent filings.
Assay Development & Validation: Ensure the long-term consistency and reliability of your diagnostic assays by using a recombinantly produced, fully defined antibody standard.

Why Choose Creative Biolabs?

Over 20 Years of Expertise: We are pioneers in antibody discovery and engineering, with a deep understanding of the nuances of antibody genetics.
PhD-Level Scientific Support: Our dedicated team provides expert consultation at every project stage, from initial inquiry to post-delivery support.
Proven Track Record: We have successfully sequenced thousands of antibodies for leading academic institutions and global biopharmaceutical companies.
Integrated Service Pipeline: Creative Biolabs is your one-stop partner. We can seamlessly transition your project from hybridoma sequencing to recombinant production, engineering, characterization, and beyond.
Commitment to Quality: Our rigorous quality management system ensures that our results are reliable, reproducible, and delivered on time, every time.

Contact Us Today for a Free Quote!

Explore Our Related Services

Leverage your antibody sequence with our comprehensive suite of downstream services:

Recombinant Antibody Production: Transition to a secure and scalable supply.
Antibody Humanization Service: Prepare your therapeutic antibody for the clinic.
De Novo Antibody Sequencing: For when you only have the protein, not the cell line.
Affinity Maturation Services: Enhance the binding properties of your antibody.
Stable Cell Line Development: For long-term, large-scale manufacturing.
Antibody Characterization Services: Fully profile the biophysical properties of your antibody.

Other optional de novo antibody sequencing Services:

Frequently Asked Questions (FAQ)

Q: What material do I need to provide?

A: The ideal starting material is a cryopreserved vial of hybridoma cells containing at least 1 million cells. We can also work with cell pellets or, in some cases, purified antibody protein (De Novo sequencing).

Q: What if my hybridoma expresses multiple antibody chains?

A: This is a common issue. Our advanced NGS platform provides the depth of coverage needed to identify multiple heavy or light chains. Our bioinformatic analysis will identify the productive, paired chains responsible for antigen binding.

Q: How do you guarantee 100% accuracy?

A: We sequence multiple independent clones for each chain and build a consensus. This redundancy allows us to eliminate PCR- or sequencing-induced errors, ensuring the final sequence is a true representation of your antibody's genetics.

Q: Can you sequence IgM antibodies?

A: Yes. Our platform and expertise are fully optimized for handling the complexities of all isotypes, including pentameric IgM antibodies, which are often challenging for other providers.

Q: What is the difference between Sanger and NGS sequencing for hybridomas?

A: While Sanger sequencing analyzes one DNA molecule at a time, NGS sequences millions simultaneously. For hybridomas, NGS is superior because it provides deep coverage to confidently identify the correct antibody sequence from a background of non-productive or aberrant chains from the myeloma fusion partner.

Reference

Mitchell, Keith G., et al. "High-volume hybridoma sequencing on the NeuroMabSeq platform enables efficient generation of recombinant monoclonal antibodies and scFvs for neuroscience research." Scientific Reports 13.1 (2023): 16200. https://doi.org/10.1038/s41598-023-43233-4 https://doi.org/10.1038/s41598-023-43233-4

×

Online Inquiry

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.